The Biointelect management team individually have greater than 20 years’ experience and proven track records in small start-up ventures and multinational corporations.

We, therefore, uniquely understand our client’s needs. We have successfully managed business units or companies and navigated complex regulatory, clinical research, quality management, commercial, product launches and business partnering strategies. Our consulting philosophy is to always offer a personalised and adaptable service. We take ownership of our projects seriously and strive for success as if we were part of your team.

Jennifer Herz is the co-founder of Biointelect, created in 2011 to provide strategic commercialisation services to the biopharmaceutical industry. Jennifer has over twenty years commercial, business development and scientific affairs experience in the biopharmaceutical industry and has held a variety of roles with responsibility for Australia, New Zealand and European markets. She was the first Managing Director of Sanofi Pasteur in Australia which was a start-up company and grew significantly over the 6 years of her tenure to be an established major provider of vaccines to the public and private market in Australia, New Zealand and the Pacific Region.

She has previously served on the Board of Medicines Australia where she led industry discussions with government related to the new funding arrangements for vaccines on the PBAC. She was also active in a variety of European and International Industry Association working groups responsible for liaison with health authorities including European Institutions and the WHO.

Jennifer is a member of the following:

·       Expert Reference Group of the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE).

·       National Health and Medical Research Council (NHMRC) – Health Research Impact Committee (HRIC) for the 2021-2024 triennium

·       Garvan Institute – Commercialisation and Innovation Advisory Panel (CIAP)

·       AAMRNet Steering Committee

Jennifer serves on several biotech Boards of Australian subsidiary companies and has significant experience in corporate governance and strategy.

Jennifer has extensive international and local network of industry, policy, scientific and clinical experts across many therapeutic areas and healthcare sectors along with global experience in multiple new product launches and start-ups at all stages of development.

Cheryl is an experienced senior leader with over 25 years experience in the pharmaceutical industry with her previous roles spanning across Sales, Marketing, Business Development, Commercial Excellence, Patient Access and General Management. Her experience includes local, regional and international responsibilities and she has lived in the US, Philippines and Australia.
Prior to joining Biointelect Cheryl was the ANZ General Manager for Novartis Oncology. She has previously worked for Servier, Wyeth, and AbbVie and during her time in industry Cheryl’s responsibilities included developing strategies and leading teams in highly specialized therapeutic areas including immunology, neuroscience, oncology and cell and gene therapies. This included local oversight of Novartis partnership for CAR-T manufacturing in Victoria. This was the first commercial CAR-T to be manufactured in Australia from a collaboration with Cell Therapies and the Peter MacCallum Cancer Institute.
Cheryl has a proven track record in developing a compelling vision, robust strategies, driving action, delivering and exceeding results year over year while leading teams across multiple functions. Strong people leadership skills have enabled Cheryl’s teams to achieve accelerated business growth through a focus on collaboration, innovation, empowerment and accountability. She has led numerous complex transformation projects and managed multiple crisis situations – creating clear plans, mapping stakeholders, assigning responsibilities and empowering teams to deliver optimal results.
Cheryl also worked five years with a Consulting organization that provided broad experience across the Asia Pacific Region with many different industries and complex supply chains.
Cheryl has a Bachelor of Science Degree, a Diploma of Education, a Master of Business Administration and is a Graduate of the Australian Institute of Company Directors. She has a passion for innovation and has completed formal innovation training with What-If Innovation (UK), Kellogg Institute (USA), Inventium (Australia) and RAW Innovation (Australia).

Karl is the co-founder of Biointelect. Karl Herz graduated from The University of Technology Sydney in Biomedicine, majoring in Biochemistry and Microbiology. He also holds a Post Graduate Certificate in Marketing.

He has over twenty-five years of varied experience in the pharmaceutical industry – from the laboratory to senior management.

Karl has extensive commercial experience (sales, marketing, business development, project management) with multinational companies, including GSK, Servier, Sanofi, Schering- Plough, Sanofi Pasteur, Sigma Pharmaceuticals and Generic Health, a subsidiary of Lupin Pharmaceuticals.

He has experience with hospitals, specialists, primary care and pharmacy channels and across a wide number of therapeutic areas ranging from OTC, generics to prescription medicines.

He is also Managing Director of Biocelect Pty Ltd which is focussed on distributing pharmaceutical and biotechnology products on behalf of companies wishing to launch their products in the Asia Pacific Region. Currently Biocelect has a prescription product progressing through the Australian Therapeutic Goods Administration, with an expected launch in the near future.

David Grainger has forty years of experience in the pharmaceutical industry, spanning Australia, New Zealand, the United States and short assignments in Brussels and London.

He completed his life sciences studies at the University of Auckland with majors in haematology and transfusion science, management studies with the New Zealand Institute of Management and health economics at Monash University in Melbourne.
David is the co-author of numerous publications on health economics and health outcomes research.

David’s industry experience includes a range of roles in sales, marketing, health outcomes research and corporate affairs. This includes ten years as the director of corporate affairs and market access in Eli Lilly’s Australian affiliate, responsible for all health outcomes research, reimbursement dossier development & pricing functions as well as the corporate affairs functions of government relations, advocacy & communications.

More recently, David held a senior role in Lilly’s international public policy group, responsible for developing and supporting the company’s external health care policy positions related to Health Technology Assessment (HTA). David also engaged extensively with governments and thought leaders in a range of markets on policy issues related to universal health coverage, formulary management, HTA, pricing and regulatory affairs.

David has had significant involvement with industry association policy efforts and for six years chaired the HTA Task Force for PhRMA International. For five years he was a member of the Board of Directors of Health Technology Assessment International, a professional society dedicated to HTA. David was also a member of the Policy Research Advisory Committee for the Office of Health Economics in London and a casual lecturer in the Masters of Pharmaceutical Medicine program at the University of New South Wales in Sydney.

Dr Patricia Vietheer has over 18 years of scientific experience in the Life Sciences industry. She holds a Bachelor of Science degree with First Class Honours from University of Queensland and a PhD in Microbiology at Monash University. She also holds an MBA majoring in Strategy & Planning at Deakin University. In 2015, Patricia completed the Molecules to Medicine Internship on Commercialisation.

A specialist in infectious diseases, molecular biology and viral immunology, Patricia’s career began in the research laboratory working on the preclinical evaluation of a versatile vaccine platform collaborating with industry. She has since held a range of roles in research; business development, project management and program development where she has helped translate scientific ideas into public health solutions. Patricia’s deep experience in early-stage preclinical R&D especially in vaccine development, technology transfer and in vivo animal studies, has been instrumental in project planning and execution often working in cross-discipline, multi-country projects driving projects towards successful outcomes.

Patricia has been a recipient of multiple awards including the NHMRC Dora Lush BioMedical Award, Australian Defence Force Prince of Wales Award and the Australian Centre for HIV & Hepatitis Virology Young Investigator’s Award. She has made substantial contribution to numerous granted patents, co-authored multiple scientific publications in peer-reviewed journals and has presented at numerous national and international conferences.

Mamta is an experienced senior finance leader with over 20+ years of experience spanning across various industries, specialising in the pharmaceutical Finance and Commercial Excellence. She comes with a strong industry experience across business Strategy, commercial decision making, financial management including business integrations and divestments. She is also very passionate about the people leadership and talent development.

Prior to joining Biointelect Mamta was the Head of finance, strategy, and business development for Novartis Oncology. During her time with Novartis, some of her key responsibilities included ensuring financial stability for the organization, providing strategic P&L, partnering & advising role to the leaders through business transformation and change management, driving the profitable growth, managing & mitigating business risk.

Mamta has a proven track record in driving performance through execution focus, navigating complex systems and processes, synthesising actionable insights, and pivoting commercial analytics to decision making with broad functional knowledge. She comes with years of experience in managing the business and financial planning processes, leading business through adoption of AI based planning model, transitioning to agile working and fostering a new mindset focusing on purpose, impact, and trust.

Mamta has also worked seven years with a Consulting organization that provided her with broad experience across different geographies, industries, and complex business models. Through this role she  demonstrated her strong communication and stakeholder management skills and contributed to the optimization of business controls and processes. Mamta is a qualified charted accountant from Institute of chartered accountants of India and certified SAP FICO consultant.

Katrina Lapham has more than fifteen years of international experience in the healthcare and biopharmaceutical industries spanning Europe, the US, Australia and emerging markets. She has recently returned to Australia from working in Europe where she led projects in market access strategy, policy and real world evidence generation. Katrina has a practical understanding of reimbursement processes, healthcare system funding models, procurement and formulary decision-making processes and priorities in major global markets.

A health economics and health policy specialist, Katrina began her career in the Australian Government Treasury as a health policy analyst and continued consulting with Deloitte Access Economics prior to working in Europe. She has had broad exposure across the health sector, working with government, industry, patient advocacy groups and other non-profit organisations, on projects across policy design and evaluation, funding model analysis and program evaluation.

Katrina recently led two multi-country real world evidence studies focusing on neurodegenerative diseases. These included primary and secondary research, with surveys and analysis of large healthcare administrative datasets. She has presented posters at the World Parkinson’s Forum in Kyoto, Japan and the International Society for Pharmacoeconomics and Outcomes Research in Copenhagen, Denmark.

Katrina is currently completing an MSc from the London School of Economics in Health Economics, Policy and Management and holds a Bachelors Degree in Economics (Honours) from the University of Western Australia. She is passionate about health economics and policy.

Jacqui Wade has over 30 years of experience in the pharmaceutical and biotech sectors. She holds a Bachelor of Science with majors in Pharmacology and Physiology. Her career spans clinical research and product commercialisation roles in multiple therapeutic areas including oncology, neuroscience, HIV, immunology and infectious diseases. She has worked for large multi-national companies, small biotech and a Clinical Research Organisation (CRO).

The early part of Jacqui’s career was spent at a generics company where she was part of the team that established a dedicated Phase I clinical trial unit. She then joined Janssen and oversaw the management of many Phase II – IV clinical trials for schizophrenia, dementia, multiple myeloma, prostate cancer and breast cancer in roles with increasing responsibility. A highlight of Jacqui’s career was the opportunity to work at Janssen-Ortho, Canada, where she was part of the Global Medical Affairs Neuroscience team for a number of key projects and led a Phase I clinical trial for obesity with a world-leading expert based in Quebec. She also held additional responsibility throughout this time as the Good Clinical Practice lead. Jacqui also spent 3 years as Clinical Research Manager at Pfizer leading the Respiratory, Infectious Disease, Oncology and Rheumatology portfolio.

Jacqui pivoted into commercial roles from 2010, initially in New Product Commercialisation and then in-line marketing where she led the successful PBS launches of first-in-class therapeutics for prostate cancer and chronic lymphocytic leukaemia. In addition, Jacqui participated in regional projects on process improvement and framework development that supported the successful execution of strategy. It was during this time that Jacqui honed her skills for cross-functional leadership, innovative and disruptive thinking, and complex problem solving.

More recently, Jacqui has worked as a Project Director for a CRO, leading a team of Project Managers, project-managing several Phase I-II clinical trials and supporting a variety of small to medium sized biotech clients. She was also Director, Business and Clinical Development for a small biotech.

Dr Besma Nash

Besma Nash has over 11 years’ experience in academia, healthcare and pharmaceutical industries. She holds a BSc(Hons) in Medical Science (University of Leeds) and a PhD in Clinical Neuroscience (University of Glasgow).

Besma’s career began as a research scientist evaluating the metabolic profile associated with congenital hydrocephalus. She then worked in various roles at the National Institute for Health and Care Excellence (NICE), incorporating research evidence into national guidance. She then transitioned into the pharmaceutical industry where she supported the launch of medicines across various therapeutic areas as a Medical Science Liaison in the UK.

More recently Besma ran a consultancy offering extensive medical affairs consulting expertise, providing medical and scientific services to the pharmaceutical and healthcare industry.

Lena Miloradovic has over 25 years of project management experience in the biotech industry. She is a certified Project Management Professional (PMP)® with the Project Management Institute USA and holds a BSc degree in Biological Science.

A specialist in the program management of vaccine development, she held senior roles in project management at CSL Research and Development (R&D) for over 20 years involving liaison with global functions and external organisations for a range of developmental vaccines. Her operational experience including manufacturing and quality, has provided a solid background for management of late-stage R&D vaccine development projects.

Highlights of Lena’s career include the internationalisation of BioCSL influenza vaccines in the U.S. and Europe and achievement of milestones in product development studies and clinical trials for early-stage CSL R&D vaccines.  Lena has headed up program management departments and contributed to the establishment of in-house program management offices.

She has recently worked with small biotech companies, assisting them with management of R&D product development, program management and establishment of quality management systems.

Azmena is a regulatory affairs professional with a track record in developing, establishing and strengthening pharmaceutical brands by being the interface between clinical development, market access teams and health authorities.

She holds a Bachelor of Pharmacy from the University of Sydney and has a broad range of experience in regulatory affairs, including provision of strategic advice, compliance support, and partnering with cross-functional teams in overcoming challenges to deliver on local and global commercial and medical objectives. She is also an advocate for diversity and inclusion, both in the workplace and in the communities we work with.

Azmena joined Biointelect in 2021 as a Regulatory Consultant. Her diverse experience across organisations and therapy areas ensures an agile, innovative and collaborative approach to supporting teams and ultimately impacting the lives of patients.

Dr Denison Chang completed a PhD in Chemical & Biomolecular Engineering at the University of Melbourne, which focussed on biosynthesis of nanomaterials and their assembly into various novel therapeutic delivery systems. He also holds a Graduate Certificate in Commercialisation of Research from Melbourne Business School, and a Bachelor of Biomedical Science (Honours) from Monash University.

Denison joins Biointelect after almost 6 years at Virbac where he held the positions of a senior scientist in new vaccine development, as well as the program manager of Virbac’s global initiative to become an animal-testing-free vaccine production company and lead the industry in animal welfare standards. From the assay development stages through to validation, registration and implementation; Denison successfully led a cross-functional international team (Australia, France, Uruguay) in replacing traditional animal tests used in the manufacture and product release processes with lab-benched-based alternatives. These in vitro tests are currently in use, one of which is a world’s first.

Prior to that, Denison’s scientific career also encompassed work as a scientist developing serological and molecular diagnostic tests at a national reference laboratory and a WHO collaborating centre for bloodborne and sexually transmitted infections; and 2 postdoctoral scientist positions in Biotech start-ups; one focused on the discovery of next generation antibodies as therapeutics; and the other on the development and manufacture of novel point-of-care tests.

Denison has a keen interest in harnessing and translating cutting edge research into practical tools or tangible products and services.

Esther S. Pronker, PhD, is an experience international business developer and consultant with a demonstrated track record in the biotechnology industry. Specializing in innovation management, business analysis, marketing and communication, project management, and stakeholder engagement. She is passionate about helping clients structure innovation to commercialize novel technologies in vaccines, drug therapies, and diagnostics by providing solutions that best fit their unique application that will also deliver on measurable business goals.

Esther holds a PhD in innovation strategy in vaccine development from the Erasmus School of Economics. She joined Biointelect in 2023 as a consultant in scientific and medical affairs, leading the development of service offerings and business development activities. Her projects span the commercialization spectrum from discovery, preclinical, and clinical projects for a wide range of infectious diseases and biosecurity agents.

She has held various roles, including as an Academic Regional Connector at the University of New England, a Research Officer at Western Sydney University, and a Business Developer at FFUND and Utrecht University. In these roles, she developed entrepreneurship-stimulating programs, wrote scientific research impact strategies, developed innovation strategies for grant applications, and bridged the gap between early-stage academic research and industry.

Esther’s skills include new lead generation, business development strategy, project management, business intelligence and analysis, CRM, training, social media marketing, and proficiency in a range of computer applications. She has co-authored multiple scientific publications, written books, and presented at numerous national and international conferences.

Nathan Fox is a health economist with more than eight years’ experience across the Australian and New Zealand pharmaceutical, medical services and devices markets.

Nathan has worked predominantly in health technology assessment and has a practical understanding of reimbursement systems and processes.  Nathan has experience developing submissions for global pharmaceutical companies to the Pharmaceutical Benefits Advisory Committee (PBAC) for reimbursement and listing on the Pharmaceutical Benefits Schedule (PBS), and to New Zealand’s Pharmaceutical Management Agency (PHARMAC).  This role has seen Nathan develop considerable experience in the costing, economic evaluation and financial implications analysis, submission preparation and commentary.

Nathan’s work for the New Zealand Government’s PHARMAC saw him responsible for considering the therapeutic positioning, health economic and financial implications of potential funding options for medicines, vaccines and rare diseases.  Here Nathan worked with key opinion leaders (KOLs) to understand the New Zealand treatment landscape, define treatment positioning and identify value propositions for funding of specific patient markets.  He also contributed to the PHARMAC prioritisation process used to compare and rank potential funding options, leading to successful funding decisions across numerous therapeutic areas including dermatology, rheumatology, gastrointestinal, oncology, rare disorders and infectious diseases.

Recently, Nathan worked as part of a contract team at the University of Sydney, critiquing and developing assessments of medical services, devices, and diagnostics for the Australian Department of Health’s Medical Services Advisory Committee (MSAC). In this role Nathan was responsible for project management of departmental engagements.  Nathan examined the clinical positioning, economic and financial impacts of potential funding options, engaging with clinical KOLs and departmental policy makers to understand newly emerging technologies and market segments.

Nathan Fox joined Biointelect in early 2021. He holds a Master’s degree in economics from Erasmus University Rotterdam, with a specialisation in health economics and a Master’s in Public Health from the University of Sydney.

Shreyas has a master’s degree in Biomedical Innovation and Development from Georgia Institute of Technology, USA. He has over 6 years of experience in medical device development, leading cross-functional teams of R&D, Operations, Manufacturing, Quality and Regulatory for development and realization of multiple products for global markets. In his last role as a Project Manager, his primary responsibilities included managing end to end product development, Project transfer and sustenance. He also has experience of setting up of multiple manufacturing lines and training of operators at the Contract Manufacturer as part of Design Transfer.

He has had rigorous regulatory clearance documentation experience, having obtained clearances for multiple Class 1 and 2 products for USFDA (510k clearances) as well as for CE (MDD and MDR). He also has experience in establishing Quality Management System (QMS) and leading more than 12 quality and regulatory audits for ISO 13485, USFDA, CE, Manufacturing License. As an integral member of the team, he assisted in improving the operational systems, processes and policies in support of Company’s objectives.


As a consultant with Biointelect, he is focussed on assisting clients and teams with strategic regulatory advice in translating medical devices from ideation all the way to commercialisation and contributing to creating impactful solutions for unmet clinical needs of the MedTech industry.

Dr. Jack Lambshead has a diverse range of experience across the scientific, biopharma and clinical sectors with a focus on cell and gene therapies (CGT). Jack holds a Bachelor of Biomedical Science (Honours) from Monash University, and a PhD in Stem Cell Biology and Materials Science between Monash, CSIRO, and the Australian Regenerative Medicine Institute (ARMI).

Jack’s research experience focused on realising the clinical potential of human pluripotent stem cells: producing antibodies against cell surface markers, and optimising/benchmarking novel synthetic surfaces for cell culture. He published numerous journal articles (first and middle author) and a book chapter, and delivered poster and oral presentations at local and international conferences.

Following his doctoral studies Jack travelled around Europe and settled in London, becoming the first employee at Medialis – a start-up medical affairs consultancy where he developed scientific and medical evidence-based non-promotional materials, mostly for rare disease therapies. This included collaboration with a European advisory board, writing several manuscripts, and the establishment of a disease severity score and a rare disease registry.

Since returning to Australia, Jack has worked with St Vincent’s Hospital Melbourne, and the Centre for Commercialisation of Regenerative Medicine (CCRM) Australia.

Jack’s local experience has included freelance medical writing, scientific editing, streamlining clinical ethics and governance applications, providing consultancy services for biotech companies, and facilitating key connections with local clinical trials services. He was also the lead project manager of a successful biotech pitch event. Through his work Jack has liaised with clinical KOLs, venture capitalists, government organisations, clinical research organisations, small biotech companies and big pharma. He has worked in clinical areas including rare diseases, oncology, neurology, and endocrinology.

Jack joined Biointelect in early 2021 as a Senior Associate. His primary interests are in strategic commercialisation and development of CGTs.

Carolyn Austin holds a Bachelor of Medical Science, majoring in Molecular Biology and Genetics, and a Bachelor of Engineering (Biomedical Engineering),  both from the University of Sydney. In her final year of her degree, Carolyn completed an honours thesis in the tissue engineering field, entitled ‘The role of Tumour Necrosis Factor Alpha in Cellular Senescence and Cellular Reprogramming’, for which she was awarded Honours Class I. During her undergraduate degree, she was awarded the Sydney Medical School Summer Research Scholarship, which she undertook at the ANZAC Research Institute modelling inherited peripheral neuropathies in worms. As a part of her degree, Carolyn completed an internship at Biointelect, in which she gained experience in cell and gene therapies and policy related to pharmaceutical development, clinical trials, and HTA.

Following this, she started at Biointelect as an associate in early 2020, and has since worked on a wide range of projects in the commercialisation of early and late stage technologies for Australian and international research organisations and biotechnology companies, as well strategic market access and policy projects for multinational pharmaceutical companies and state governments. Her experience spans multiple therapeutic areas, including antimicrobial resistance, infectious diseases, oncology, rare diseases, genomics and regenerative medicine, across various technology types, including therapeutics vaccines, diagnostics, digital therapeutics, but has a particular interest in cell and gene therapies. She was recently promoted to senior associate, and is excited to keep working with clients in the life science sector to develop and commercialise innovative therapies.


Jemima James achieved her Bachelor of Science (Neuroscience) and Master of Biomedical Science (Stem Cell & Neural Development) from the University of Melbourne. As part of her master’s degree, she conducted research at The Florey Institute of Neuroscience and Mental Health investigating the utility of induced pluripotent stem cells in modelling Parkinson’s disease for drug discovery.

After completing her master’s degree Jemima worked as a pharmaceutical sales representative where she helped launch three new medicinal cannabis products into the adult and pediatric markets. Following this, Jemima worked for GSK as a Vaccines Account Manager where she aided in introducing a new adult vaccine into the market.

Jemima joined Biointelect as an associate in 2022. She is passionate about regenerative medicine and preventative healthcare and is excited to continue helping to bring innovative therapies to patients.

Sophie has a strong academic foundation in business, experience in consulting and a passion for healthcare, enhancing patient access and delivering improvements in health outcomes.

Prior to joining KPMG’s Management Consulting practice, Sophie graduated from the University of Sydney with a Bachelor of Commerce, with majors in Marketing and International Business and a Bachelor of Advanced Studies in Business. A highlight from Sophie’s studies includes her experience with Accenture in the United Kingdom as an external student consultant. Through this experience, she worked in an interdisciplinary team to design digital solutions for the UK National Health Service, which aim to reduce key health challenges encountered by elderly populations.

Sophie has a variety of consulting experience across the healthcare and aged care sectors, having begun her career in KPMG’s Policy, Economics and Public Impact practice, aligned to the Health, Ageing and Human Services advisory sector. During her time at KPMG, Sophie was involved in a range of engagements, working with both public and private sector health and aged care clients, leading to her understanding of their operating environment, workflow, and strategic and operational activities. She has developed experience in organisational strategy and improvement, program and service evaluation, business case development and organisational structure and redesign across a variety of health-related domains, including digital health and health programs. Sophie has experience conducting a broad range of consulting activities, including stakeholder engagement and consultation, project management, research and data analysis, strategy and report development.

During her studies, Sophie worked as a dental assistant, providing her with experience working within a clinical setting, whilst strengthening her interest in preventative healthcare, patient access to services and the clinical environment.

Mark Boylett is a graduate of the National University of Ireland Galway where he studied a postgraduate MSc in Health Economics, having previously completed a master’s in pharmacy from the University of Brighton.

After spending time working as a pharmacist, and pursuing an MSc in health economics, Mark started working in the pharmaceutical industry in a health economics capacity for a large multinational pharmaceutical company. During his time here he supported several value and access business functions ranging from country to global level structures.

Mark started developing his market access experience during a placement with the UK Oncology team where he stood in as a HE&OR manager helping oversee all health economic and market access activities for two oncology brands. This included supporting the preparation of a submission to NICE. This role saw Mark develop his HEOR and market access skill set as he provided input to global health economic deliverables, before assisting with their UK adaptation, whilst also acting as the HEOR point of contact for activities in cross functional workstreams.

Primarily Mark however spent his time supporting global value and access oncology teams such as Melanoma, Breast Cancer, and Immuno-oncology franchises. Here he helped with a wide range of activities including supporting the preparation of market access launch activities, to life cycle management activities of existing brands. The time spent with the global structure of the business allowed Mark to develop a keen sense of the strategic components involved in a successful product launch. Additionally, Mark has spent time working with economic modelling teams assisting with projects such as adaptation and localisation of global budget impact models to European markets.


Mark joined Biointelect in 2022. He is passionate about optimising patient care and helping to address the unmet needs of patients by improving access innovative medicines.

Crystal Nguyen completed her Master of Biomedical Sciences (Stem Cells & Developmental Biology) and PhD at the University of Melbourne, where she managed a multifaceted research project focusing on the development of a gene therapy for degenerative eye diseases. Crystal is the author of seven journal articles and has given numerous presentations at local and international conferences, including an award-winning digital presentation. Crystal held several leadership roles at graduate researchers’ organisations and contributed to fostering informational exchange and collaborations between research institutes.

Crystal gained her industry experience as an intern at the Research, Innovation, and Commercialisation team at the University of Melbourne. During her time here, she conducted market research and competitive analysis to assess the patentability and commercial potential of new technologies developed at the university.

Crystal joined Biointelect in 2023. She is passionate about leveraging biomedical innovation to improve people’s health and well-being.

Frances Ryan graduated a Master of Engineering (Biomedical with Business) from the University of Melbourne with First Class honours. She also holds a Bachelor of Biomedicine (Immunology) degree. For her master’s thesis she developed a medical device prototype for blood collection, which won three awards for its potential to improve patient outcomes.


She has gained experience in a US-based startup validating a biopreservation technology and completed biomechanics research at the University of Melbourne’s Integrative Cartilage Research Group. For a healthcare fund, Frances wrote investor insight reports, conducting scientific and economic evaluation of key healthcare markets and companies.


Frances joined Biointelect in 2023 as an Associate. She has a keen interest in the commercialisation of medical devices and is excited to help impactful healthcare innovations reach patients and succeed in the market.

Xin Yuan Quek graduated from Macquarie University with a Bachelor of Economics degree.

She started her work as the Policy Researcher at the Australian Taxpayers’ Alliance where she co-wrote an economics research paper, conducted research, implemented a stakeholder relations system and represented the company in media interviews.

Xin Yuan then continued her work at the NSW Ministry of Health as a policy officer. She conducted economic evaluation on health and medical research programs, formulated a risk management process for the programs and worked with various grant leaders to establish grant management guidelines as well as the principles for future economic evaluations.

Xin Yuan has published op-eds on economic policies in publications such as The Canberra Times, The Daily Telegraph and International Policy Digest. She has also received podcast and radio interviews for her work.

Xin Yuan joined Biointelect in 2022. She is passionate about health economics and the complexities that lay within it.

Jessica joined Biointelect in 2022 as a Project officer to provide Business Support to our Consulting Teams and Clients.

Jessica brings 6+ years of experience across a wide range of industries including Finance, Property and Recruitment.

She is passionate about creating a positive culture that focuses on producing ideas to support the business and looks forward to implementing processes that will enable Biointelect to best support our clients.

Vasanthi joined Biointelect in July 2023 as a Project officer to provide Business Support to our Consulting Teams and Clients.

Vasanthi has extensive experience working closely with SMEs spearheading teams working with Client Engagement, Business Development and Operations. Vasanthi’s strong business acumen will be valuable in understanding the needs of clients and providing them with tailored solutions. Vasanth’s goal is to forge strong business partnerships with companies, both internally within Biointelect and externally with clients and partners.

She is enthusiastic to learn about the pharma industry.

Benjamin Herz Joined Biointelect in late 2020 as an office assistant. Benjamin has two and a half years retail experience working casually at Harris Farm Markets, in this time he undertook roles such as customer service, inventory management, merchandise displays and working at the checkout. Furthermore, Benjamin has worked as an independent contractor for Salmat HUB, in this time he delivered pamphlets containing advertising material to residents for large retailers such as Myer, Woolworths and more.

Benjamin also speaks French and is passionate about widening his horizons. Due to this Benjamin has developed good customer engagement skills, a working knowledge of the day-to-day operations of a business and a positive outlook on the workplace.

Benjamin hopes to bring these skills as well as his love for science (developed in high school) to Biointelect so that he can help with general office admin, streamlining operating procedures and maintaining technical aspects of the business such as SharePoint and WorkflowMax.